Thyroid Hürthle Cell Carcinoma: Clinical, Pathological, and Molecular Features

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Dec 30

PMID 33374707

Citations 19

Authors

Shoko Kure

Ryuji Ohashi

Affiliations

Soon will be listed here.

Abstract

Hürthle cell carcinoma (HCC) represents 3-4% of thyroid carcinoma cases. It is considered to be more aggressive than non-oncocytic thyroid carcinomas. However, due to its rarity, the pathological characteristics and biological behavior of HCC remain to be elucidated. The Hürthle cell is characterized cytologically as a large cell with abundant eosinophilic, granular cytoplasm, and a large hyperchromatic nucleus with a prominent nucleolus. Cytoplasmic granularity is due to the presence of numerous mitochondria. These mitochondria display packed stacking cristae and are arranged in the center. HCC is more often observed in females in their 50-60s. Preoperative diagnosis is challenging, but indicators of malignancy are male, older age, tumor size > 4 cm, a solid nodule with an irregular border, or the presence of psammoma calcifications according to ultrasound. Thyroid lobectomy alone is sufficient treatment for small, unifocal, intrathyroidal carcinomas, or clinically detectable cervical nodal metastases, but total thyroidectomy is recommended for tumors larger than 4 cm. The effectiveness of radioactive iodine is still debated. Molecular changes involve cellular signaling pathways and mitochondria-related DNA. Current knowledge of Hürthle cell carcinoma, including clinical, pathological, and molecular features, with the aim of improving clinical management, is reviewed.

Citing Articles

Outcome analysis of differentiated thyroid cancer: Experience from tertiary care in Karachi.

Furqan S, Ahmed A, Batool S, Islam N Pak J Med Sci. 2024; 40(11):2631-2635.

PMID: 39634861 PMC: 11613377. DOI: 10.12669/pjms.40.11.7036.

Liquid biopsy in cancer current: status, challenges and future prospects.

Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J Signal Transduct Target Ther. 2024; 9(1):336.

PMID: 39617822 PMC: 11609310. DOI: 10.1038/s41392-024-02021-w.

Prognostic Models Using Machine Learning Algorithms and Treatment Outcomes of Papillary Thyroid Carcinoma Variants.

Alshwayyat S, Kamal H, Ghammaz O, Alshwayyat T, Alshwayyat M, Odat R Cancer Rep (Hoboken). 2024; 7(12):e70071.

PMID: 39614618 PMC: 11607134. DOI: 10.1002/cnr2.70071.

Molecular Markers in Follicular and Oncocytic Thyroid Carcinomas: Clinical Application of Molecular Genetic Testing.

Belaiche A, Morand G, Turkdogan S, Kang E, Forest V, Pusztaszeri M Curr Oncol. 2024; 31(10):5919-5928.

PMID: 39451745 PMC: 11506192. DOI: 10.3390/curroncol31100441.

Comparison of prognosis between oncocytic thyroid carcinoma and follicular thyroid carcinoma: a population-based propensity score matching analysis.

Peng H, Ding H, Li X, Wang W, Wang X, Gu J Eur Arch Otorhinolaryngol. 2024; 282(2):993-1003.

PMID: 39259318 DOI: 10.1007/s00405-024-08965-7.

References

Canberk S, Onenerk M, Gunes P, Sayman E, Kilicoglu G . Oncocytic Variant of Medullary Thyroid Carcinoma. Endocr Pathol. 2015; 26(4):320-3. DOI: 10.1007/s12022-015-9389-0. View

Sobrinho-Simoes M, Maximo V, Castro I, Fonseca E, Soares P, Garcia-Rostan G . Hürthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. Int J Surg Pathol. 2005; 13(1):29-35. DOI: 10.1177/106689690501300104. View

Ding L, Jiang Y, Yang W . Approach the Invasive Potential with Hurthle Cell Tumors of Thyroid. Pathol Oncol Res. 2018; 25(2):697-701. DOI: 10.1007/s12253-018-0546-x. View

Wasvary H, Czako P, Poulik J, Lucas R . Unilateral lobectomy for Hurthle cell adenoma. Am Surg. 1998; 64(8):729-32; discussion 732-3. View

Angell J, Lindner D, Shapiro P, Hofmann E, Kalvakolanu D . Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem. 2000; 275(43):33416-26. DOI: 10.1074/jbc.M003929200. View

Cavadas B, Pereira J, Correia M, Fernandes V, Eloy C, Sobrinho-Simoes M . Genomic and transcriptomic characterization of the mitochondrial-rich oncocytic phenotype on a thyroid carcinoma background. Mitochondrion. 2018; 46:123-133. DOI: 10.1016/j.mito.2018.04.001. View

Maximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A . Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer. 2005; 92(10):1892-8. PMC: 2361763. DOI: 10.1038/sj.bjc.6602547. View

Wang Y, Zhang S . Quantitative assessment of the association between GNB3 C825T polymorphism and cancer risk. J BUON. 2014; 19(4):1092-5. View

Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, Espina V . Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res. 2010; 70(21):8874-85. DOI: 10.1158/0008-5472.CAN-10-1994. View

10.

Zheng X, Cui D, Xu S, Brabant G, Derwahl M . Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells. Int J Oncol. 2010; 37(2):307-15. DOI: 10.3892/ijo_00000679. View

11.

Ito Y, Amino N, Yokozawa T, Ota H, Ohshita M, Murata N . Ultrasonographic evaluation of thyroid nodules in 900 patients: comparison among ultrasonographic, cytological, and histological findings. Thyroid. 2007; 17(12):1269-76. DOI: 10.1089/thy.2007.0014. View

12.

Maizlin Z, Wiseman S, Vora P, Kirby J, Mason A, Filipenko D . Hurthle cell neoplasms of the thyroid: sonographic appearance and histologic characteristics. J Ultrasound Med. 2008; 27(5):751-7. DOI: 10.7863/jum.2008.27.5.751. View

13.

Coca-Pelaz A, Vivanco-Allende B, Alvarez-Marcos C, Suarez-Nieto C . Multifocal papillary thyroid carcinoma associated with primary amyloid goiter. Auris Nasus Larynx. 2011; 39(5):549-51. DOI: 10.1016/j.anl.2011.09.003. View

14.

Ni J, Wang Y, Cheng X, Teng F, Wang C, Han S . Pathogenic Heteroplasmic Somatic Mitochondrial DNA Mutation Confers Platinum-Resistance and Recurrence of High-Grade Serous Ovarian Cancer. Cancer Manag Res. 2020; 12:11085-11093. PMC: 7646460. DOI: 10.2147/CMAR.S277724. View

15.

Tanaka A, Matsuse M, Saenko V, Nakao T, Yamanouchi K, Sakimura C . mRNA Expression as a Novel Prognostic Marker in Papillary Thyroid Carcinomas. Thyroid. 2019; 29(8):1105-1114. DOI: 10.1089/thy.2018.0695. View

16.

Gasparre G, Porcelli A, Bonora E, Pennisi L, Toller M, Iommarini L . Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A. 2007; 104(21):9001-6. PMC: 1885617. DOI: 10.1073/pnas.0703056104. View

17.

Matias C, Nunes J, Sobrinho L, Soares J . Giant mitochondria and intramitochondrial inclusions in benign thyroid lesions. Ultrastruct Pathol. 1991; 15(3):221-9. DOI: 10.3109/01913129109021884. View

18.

Anila K, Nayak N, George P, Jayasree K . Cytomorphologic Spectrum of Hurthle Cell Lesions of Thyroid: A Study of 54 Cases. Gulf J Oncolog. 2018; 1(26):6-10. View

19.

Nesland J, Sobrinho-Simoes M, Holm R, Sambade M, JOHANNESSEN J . Hürthle-cell lesions of the thyroid: a combined study using transmission electron microscopy, scanning electron microscopy, and immunocytochemistry. Ultrastruct Pathol. 1985; 8(4):269-90. DOI: 10.3109/01913128509141518. View

20.

Liu X, Kim C, Yang J, Jemmerson R, Wang X . Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996; 86(1):147-57. DOI: 10.1016/s0092-8674(00)80085-9. View